Climate Change Data

Sino Biopharmaceutical Limited

Climate Impact & Sustainability Data (2023)

Reporting Period: 2023

Environmental Metrics

Total Carbon Emissions:239,239.61 tCO2e/year
Scope 1 Emissions:17,046.22 tCO2e/year
Scope 2 Emissions:222,193.40 tCO2e/year
Scope 3 Emissions:Not disclosed
Renewable Energy Share:7,504.19 MWh representing 76.64% increase from 2022
Total Energy Consumption:479,097.61 MWh/year
Water Consumption:3,038,272.05 m3/year
Waste Generated:7,624.66 tons/year (hazardous) and 3,602.59 tons/year (non-hazardous)
Carbon Intensity:8.89 tCO2e/RMB1 million revenue

ESG Focus Areas

  • Cure
  • Accessible
  • Relationship
  • Environmental

Environmental Achievements

  • 13% reduction in GHG emission density compared to the benchmark year (2021)
  • 76.64% surge in clean energy consumption from the previous year
  • 5% decrease in packaging material consumption compared to the previous year
  • Completed carbon inventories of two pilot units and identified emission reduction opportunities

Social Achievements

  • Released Employee Development Policy of Sino Biopharmaceutical, emphasizing knowledge and technology transfer between employees
  • Invested RMB56,777,400 in public welfare endeavors, with 4,196 employees participating in public welfare activities totaling 5,195.5 hours

Governance Achievements

  • Implemented group-wide integration in various business areas (BD, digital innovation, intellectual property rights, retail, procurement, and auditing)
  • Completed identifying carbon reduction opportunities for pilot units towards carbon neutrality and rigorously implemented ESG risk management measures tailored for the supply chain across member companies
  • Upgraded MSCI ESG rating to “A”

Climate Goals & Targets

Long-term Goals:
  • Not disclosed
Medium-term Goals:
  • Not disclosed
Short-term Goals:
  • Reduce GHG emissions per RMB1 million of revenue by 20% by 2025 (with 2021 as the benchmark year)
  • Reduce hazardous waste discharges per RMB1 million of revenue by 10% by 2025 (with 2021 as the benchmark year)

Environmental Challenges

  • Major global public health events (outbreaks of infectious diseases)
  • National policy for centralized procurement (reducing profit margins of generic drugs)
  • Geopolitical risks (sanctions, restrictions on technology introduction and international strategic cooperation)
Mitigation Strategies
  • Developing contingency plans for public health events
  • Consolidating advantageous therapeutic areas, increasing investment in innovative R&D, establishing differentiated competitive advantages, and optimizing production processes
  • Continuously monitoring and assessing general economic and political trends, maintaining close interaction with stakeholders, and developing action plans

Supply Chain Management

Supplier Audits: Over 600/year

Responsible Procurement
  • Supplier ESG Code of Conduct
  • Standard of Sino Biopharmaceutical for ESG-based Classification Management of Suppliers
  • Environment, Health and Safety (EHS) Agreement for Suppliers
  • Supplier integrity agreement

Climate-Related Risks & Opportunities

Physical Risks
  • Extreme weather conditions (typhoons, extreme precipitation)
  • Rising average temperatures (increased energy consumption)
Transition Risks
  • Policy and legal risk (carbon emissions regulations)
  • Technical risk (upgrades for low-carbon operations)
  • Market risk (increased prices of raw materials)
Opportunities
  • Emerging technologies (enhancing operational efficiencies)
  • Energy sources (increasing share of clean energy)
  • Markets (increased demand for medicines due to climate change)

Reporting Standards

Frameworks Used: GRI Standards, IFRS S1, IFRS S2, UNGC Ten Principles, UN’s 2030 Agenda for Sustainable Development, UN’s 17 Sustainable Development Goals (SDGs)

Certifications: ISO 14001, ISO 45001, ISO 50001, ISO 9001

Third-party Assurance: British Standards Institution Management Systems Certification (Beijing) Co., Ltd.

UN Sustainable Development Goals

  • Not disclosed

Not disclosed

Sustainable Products & Innovation

  • Not disclosed

Awards & Recognition

  • 2023 Forbes China Best Employers
  • 2023 Forbes China Most Digitally Responsible Employers
  • 2023 Insightful Employer Selection: Happy Company Award
  • Yicai The Corporate Social Responsibility Ranking in China: Social Innovation Contribution Award
  • Green Factory at the National Level (CT Tianqing)
  • Green Factory in Jiangsu Province (NJCTT, CT Fenghai)
  • 2023 Green Development Leaders (CT Tianqing Lianyungang Runzhong Pharmaceutical Co., Ltd.)
  • Ranked 36th among the Top 100 China’s Overseas Listed Companies for ESG and Low Carbon
  • China ESG Golden Awards 2023 – Outstanding Enterprise in Social Responsibility
  • Top 100 China’s Innovative Pharmaceutical Enterprises in 2023
  • China’s Top 10 Listed Pharmaceutical Companies by R&D Innovation in 2023
  • Innovative Drug Company of the Year
  • The Case of BRI Implementation
  • Top 100 Enterprises in China – Comprehensive Strength in Medicine R&D in 2023
  • Top 100 Enterprises in China – Chemical Medicine R&D Strength in 2023
  • Top 50 Enterprises in China – Biological Medicine R&D Strength in 2023
  • Top 100 Pharmaceutical Companies by Competitiveness in 2023
  • Top 100 Chinese Chemical Pharmaceutical Companies in 2022
  • 2023 Best Industrial Enterprise for Pharmaceutical R&D Product Line in China
  • Jiangsu Governor’s Quality Award (CT Tianqing)
  • Demonstration Enterprises for Drug Production Quality Management Standards in Jiangsu Province (CT Tianqing)
  • “Quality Benchmark” of Jiangsu Province in 2023 (CT Tianqing)